Synthesis of Novel 4-methylthiocoumarin and Comparison with Conventional Coumarin Derivative As a Multi-target-directed Ligand in Alzheimer's Disease

Overview

Journal 3 Biotech

Publisher Springer

Specialty Biotechnology

Date 2020 Nov 13

PMID 33184595

Citations 2

Authors

Shivani Kumar

Yogesh Kumar Tyagi

Manoj Kumar

Suresh Kumar

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a multifactorial disorder characterized by cognitive deficit and memory loss. The pathological feature of the disease involves β-amyloid senile plaques, reduced levels of acetylcholine neurotransmitter, oxidative stress and neurofibrillary tangles formation within the brain of AD patients. The present study aims to screen the inhibitory activity of newly synthesized and existing novel 4-methylthiocoumarin derivative against acetylcholinesterase, butyrylcholinesterase, BACE1, β-amyloid aggregation and oxidative stress involved in the AD pathogenesis. The in vitro assays used in this study were Ellman's assay, FRET assays, Thioflavin T, transmission electron microscopy, circular dichroism, FRAP, and TEAC. Molecular docking and dynamics studies were performed to correlate the results. C3 and C7 (thiocoumarin derivatives) were found to be the most potent inhibitors of acetylcholinesterase (IC-5.63 µM) and butyrylcholinesterase (IC-3.40 µM) using Ellman's assays. Enzyme kinetic studies showed that C3 and C7 compounds followed by the mixed mode of inhibition using LB plot. C3 also moderately inhibited the BACE1 using FRET assay. C3 inhibited the fibrillization of β-amyloid peptides in a concentration-dependent manner as observed by Thioflavin T, TEM studies and Circular dichroism data. Molecular modeling studies were performed to understand the probable mode of binding of C3 and C7 in the binding pocket of acetylcholinesterase, butyrylcholinesterase, BACE1 and amyloid β peptides. This indicates the important role of hydrophobic interactions between C3 and acetylcholinesterase. C3 also exhibited significant antioxidant potential by FRAP and TEAC assays. Hence, C3 might serve as a promising lead for developing novel multi target-directed ligand for the treatment of AD.

Citing Articles

An overview of structure-based activity outcomes of pyran derivatives against Alzheimer's disease.

Almalki F Saudi Pharm J. 2023; 31(6):998-1018.

PMID: 37234350 PMC: 10205782. DOI: 10.1016/j.jsps.2023.04.030.

Thiocoumarins: From the Synthesis to the Biological Applications.

Matos M, Santana L, Uriarte E, Borges F Molecules. 2022; 27(15).

PMID: 35956851 PMC: 9369797. DOI: 10.3390/molecules27154901.

References

Wang Y, Wang H, Chen H . AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. Curr Neuropharmacol. 2016; 14(4):364-75. PMC: 4876592. DOI: 10.2174/1570159x14666160119094820. View

Yusufzai S, Khan M, Sulaiman O, Osman H, Lamjin D . Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer's disease. Chem Cent J. 2018; 12(1):128. PMC: 6768047. DOI: 10.1186/s13065-018-0497-z. View

Chen Y, Huang H, Chyan C, Shiao M, Lin T, Chen Y . The effect of Abeta conformation on the metal affinity and aggregation mechanism studied by circular dichroism spectroscopy. J Biochem. 2006; 139(4):733-40. DOI: 10.1093/jb/mvj083. View

Ranade D, Bapat A, Ramteke S, Joshi B, Roussel P, Tomas A . Thiosemicarbazone modification of 3-acetyl coumarin inhibits Aβ peptide aggregation and protect against Aβ-induced cytotoxicity. Eur J Med Chem. 2015; 121:803-809. DOI: 10.1016/j.ejmech.2015.07.028. View

Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, DUrsi A, Temussi P . Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem. 2002; 269(22):5642-8. DOI: 10.1046/j.1432-1033.2002.03271.x. View

Chen Z, Zhong C . Oxidative stress in Alzheimer's disease. Neurosci Bull. 2014; 30(2):271-81. PMC: 5562667. DOI: 10.1007/s12264-013-1423-y. View

Chidan Kumar C, Loh W, Ooi C, Quah C, Fun H . Structural correlation of some heterocyclic chalcone analogues and evaluation of their antioxidant potential. Molecules. 2013; 18(10):11996-2011. PMC: 6270477. DOI: 10.3390/molecules181011996. View

Perez-Iratxeta C, Andrade-Navarro M . K2D2: estimation of protein secondary structure from circular dichroism spectra. BMC Struct Biol. 2008; 8:25. PMC: 2397409. DOI: 10.1186/1472-6807-8-25. View

Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta S, Singh S . Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. Eur J Med Chem. 2018; 148:436-452. DOI: 10.1016/j.ejmech.2018.02.035. View

10.

Hamulakova S, Poprac P, Jomova K, Brezova V, Lauro P, Drostinova L . Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. J Inorg Biochem. 2016; 161:52-62. DOI: 10.1016/j.jinorgbio.2016.05.001. View

11.

DE POI L, PITZURRA M, Negri M . [Antibacterial properties of thiocoumarin and its 7-substituted derivatives]. Boll Chim Farm. 1962; 101:376-9. View

12.

Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H . Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease. J Pharmacol Exp Ther. 2017; 362(3):413-423. DOI: 10.1124/jpet.117.241653. View

13.

Nair S, Reddy N, Hareesha K . Exploiting heterogeneous features to improve in silico prediction of peptide status - amyloidogenic or non-amyloidogenic. BMC Bioinformatics. 2012; 12 Suppl 13:S21. PMC: 3278838. DOI: 10.1186/1471-2105-12-S13-S21. View

14.

Hasselgren C, Dellve L, Ekbrand H, Zettergren A, Zetterberg H, Blennow K . Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with ɛ4. SSM Popul Health. 2018; 5:171-179. PMC: 6043817. DOI: 10.1016/j.ssmph.2018.06.009. View

15.

Benzie I, Strain J . The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239(1):70-6. DOI: 10.1006/abio.1996.0292. View

16.

Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W . Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27(3):221-34. DOI: 10.1007/s10822-013-9644-8. View

17.

Anand P, Singh B, Singh N . A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg Med Chem. 2012; 20(3):1175-80. DOI: 10.1016/j.bmc.2011.12.042. View

18.

Zhu Z, Yang T, Zhang L, Liu L, Yin E, Zhang C . Inhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative. Eur J Med Chem. 2019; 168:330-339. DOI: 10.1016/j.ejmech.2019.02.052. View

19.

Friesner R, Murphy R, Repasky M, Frye L, Greenwood J, Halgren T . Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21):6177-96. DOI: 10.1021/jm051256o. View

20.

Butterfield D, Sultana R . Methionine-35 of aβ(1-42): importance for oxidative stress in Alzheimer disease. J Amino Acids. 2012; 2011:198430. PMC: 3268025. DOI: 10.4061/2011/198430. View